Vaxeal Research receives a grant from the French National Research Agency
The objective of this project is the development of an optimized LSP-based cancer therapeutic vaccine targeting the SVX-1 tumor antigen to bring this vaccine as a first-generation product in human trial. The Work Program will investigate the effects of various factors, added or coupled to the LSPs, to boost their immunogenicity and anti-tumoral activity. The key factors to be tested include the LSPs chemical composition and synergy with immune adjuvants. Spontaneous immune responses against our proprietary LSPs will be also assessed in cancer patients to rationaly guide the selection of patients for the clinical trials.
The consortium brings together diverse advanced expertise in tumor immunology and vaccine formulation, including T-cell response immuno-monitoring in clinical samples, pre-clinical animal models, and clinical trials. It involves both clinicians and scientists from three research-intense accademic laboratories (INSERM ; Hospital Pompidou, CEA) with Vaxeal.
About Vaxeal Research SAS
Created in 2009, Vaxeal Holding SA is an SME headquartered in Vevey (Switzerland). The company, in partnership with leading International Research Institutes, is developing therapeutic vaccines in combination with immuno-modulatory drugs for the treatment of cancers and infectious diseases. The cutting-edge immunotherapies are protected by several patent families. Our initial programs have reached the pre-clinical stage in major disease segments, and are expected to enter into clinical trials in Europe in 2016. Vaxeal is member of Vaccines Europe, and the European Biopharmaceutical Enterprises. The company received a special MIT award for “its remarkable breakthrough in the field of vaccines”.
About the French National Research Agency (ANR)
The French National Research Agency was created in 2005 to organise the funding of projects whose end-purpose is to give impetus to the research sector. Firmly committed to addressing this issue, which is of crucial importance for the competitiveness of France and the international visibility of its research work, the ANR places great importance on: fostering creativity and openness, stimulating new ideas and partnerships, targeting research efforts on economic and societal priorities determined at the highest level of State and through consultation with the other research players, encouraging inter-disciplinary actions, intensifying links between the public and private sectors, developing international and European collaborations The main challenges the ANR works on are part of the European Strategic Agenda. Please visit www.agence-nationale-recherche.fr for more information.
- Posted by Elliot Willcox
- On 18 December 2013
- 0 Comments